Results 261 to 270 of about 856,230 (338)

CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target

open access: yesAdvanced Science, EarlyView.
CircSMEK1 is downregulated in MASH/HCC and predicts poor prognosis. It suppresses tumor progression by promoting hnRNPK ubiquitination and inhibiting the IGF2/PI3K/AKT axis, while its loss activates immunosuppressive cancer‐associated fibroblasts. Serum circSMEK1 serves as a non‐invasive diagnostic biomarker, and its restoration potently inhibits HCC ...
Peilan Guo   +15 more
wiley   +1 more source

T Cell Glycoengineering to Modulate Immune‐Tumor Crosstalk: A Universal Non‐Genetic Strategy for Enhanced Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study describes a T cell surface engineering strategy that integrates polymer materials with tumor immunology, aiming to achieve broad‐spectrum anti‐tumor applications of glycopolymer‐engineered T (G‐T) cells via non‐genetic modification. Glycopolymer engineering generally modulates immune‐tumor crosstalk through specific cell‐cell interactions ...
Lihua Yao   +8 more
wiley   +1 more source

Proteome Analysis of the Six-Eyed Sand-Spider <i>Sicarius thomisoides</i> Venom. [PDF]

open access: yesToxins (Basel)
Arán-Sekul T   +5 more
europepmc   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

open access: yesAdvanced Science, EarlyView.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy